In the SURMOUNT-1 trial, obese patients without diabetes who received tirzepatide with monthly lifestyle counseling lost 20.9% of baseline weight at 72 weeks (versus 3.1% for placebo) with ...
Following positive results from its SURMOUNT-5 trial, Eli Lilly’s Zepbound (tirzepatide) will surpass Novo Nordisk’s Weogvy (semaglutide) in the obesity treatment market, according to a ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...
Medicare now covers Eli Lilly's Zepbound for obstructive sleep apnea, FDA-approved for obesity and sleep apnea treatment, ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback